Base de dados : MEDLINE
Pesquisa : D02.886.640.074.500 [Categoria DeCS]
Referências encontradas : 8365 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 837 ir para página                         

  1 / 8365 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Roesler, Rafael
Texto completo
[PMID]:28452904
[Au] Autor:Marchezan J; Becker M; Schwartsmann G; Ohlweiler L; Roesler R; Renck LB; Gonçalves MMM; Ranzan J; Riesgo RDS
[Ad] Endereço:*Postgraduate Program in Child and Adolescent Health, School of Medicine, Federal University of Rio Grande do Sul; †Department of Pediatrics, Child Neurology Unit, Hospital de Clínicas de Porto Alegre; ‡Department of Internal Medicine, School of Medicine, Cancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), §Department of Pharmacology, Institute for Basic Health Sciences, Cancer and Neurobiology Laboratory, Experimental Research Center, Clinical Hospital (CPE-HCPA), and ∥Department of Pediatrics, Child Neurology Unit, Postgraduate Program in Child and Adolescent Health, School of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil.
[Ti] Título:A Placebo-Controlled Crossover Trial of Gastrin-Releasing Peptide in Childhood Autism.
[So] Source:Clin Neuropharmacol;40(3):108-112, 2017 May/Jun.
[Is] ISSN:1537-162X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: The aim of this study was to evaluate the efficacy, safety, and tolerability of gastrin-releasing peptide (GRP) compared with placebo in autism spectrum disorder symptoms. METHODOLOGY: This is a randomized, double-blind, placebo-controlled crossover trial using GRP 160 pmol/kg for 4 consecutive days in 10 children with autism. Outcomes were measured by the Aberrant Behavior Checklist (ABC) scale. RESULTS: All participants were boys, aged between 4 and 9 years. There was a reduction in the scores of the ABC range and its subscales after use GRP and placebo. The reduction was more prominent with GRP, particularly in the subscale "hyperactivity and noncompliance," but there was no statistical difference between the results (P = 0.334). After a week of infusion, 5 children showed improvement of 25% or greater in the total score of the ABC scale with GRP use and 2 with placebo use; however, there was no statistical difference (P = 0.375). There were no adverse effects, changes in vital signs, or laboratory abnormalities associated with the use of GRP. CONCLUSIONS: The results of this study, despite the small sample size, reinforce previous data on the safety of the GRP in short-term use. There is a need for further research with other designs and a larger sample size to evaluate the efficacy and safety of GRP in children with autism.
[Mh] Termos MeSH primário: Transtorno do Espectro Autista/tratamento farmacológico
Comportamento Infantil/efeitos dos fármacos
Peptídeo Liberador de Gastrina/uso terapêutico
Psicotrópicos/uso terapêutico
[Mh] Termos MeSH secundário: Antiulcerosos/uso terapêutico
Anticonvulsivantes/efeitos adversos
Anticonvulsivantes/uso terapêutico
Antipsicóticos/efeitos adversos
Antipsicóticos/uso terapêutico
Transtorno do Espectro Autista/fisiopatologia
Transtorno do Espectro Autista/psicologia
Criança
Pré-Escolar
Terapia Combinada/efeitos adversos
Estudos Cross-Over
Manual Diagnóstico e Estatístico de Transtornos Mentais
Método Duplo-Cego
Quimioterapia Combinada/efeitos adversos
Seguimentos
Peptídeo Liberador de Gastrina/administração & dosagem
Peptídeo Liberador de Gastrina/efeitos adversos
Seres Humanos
Infusões Intravenosas
Masculino
Omeprazol/uso terapêutico
Escalas de Graduação Psiquiátrica
Psicotrópicos/administração & dosagem
Psicotrópicos/efeitos adversos
Reprodutibilidade dos Testes
Índice de Gravidade de Doença
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anti-Ulcer Agents); 0 (Anticonvulsants); 0 (Antipsychotic Agents); 0 (Psychotropic Drugs); 80043-53-4 (Gastrin-Releasing Peptide); KG60484QX9 (Omeprazole)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1097/WNF.0000000000000213


  2 / 8365 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29220339
[Au] Autor:Chuong MC; Taglieri CA; Kerr SG
[Ad] Endereço:School of Pharmacy, MPCHS University, Boston, Massachusetts.
[Ti] Título:To Flavor or Not to Flavor Extemporaneous Omeprazole Liquid.
[So] Source:Int J Pharm Compd;21(6):500-512, 2017 Nov-Dec.
[Is] ISSN:1092-4221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Omeprazole is a proton pump inhibitor used to treat the symptoms of gastro esophageal reflux disease, ulcers, excess stomach acid, infection with Helicobacter pylori, and to control the gastric side effects of various drugs. The approved dosage forms in the U.S. are powder in compounding kits, delayed-release granules for oral suspension, oral delayed-release tablets, and oral delayed-release capsules. An extemporaneously compounded unsweetened oral liquid method, published in the International Journal of Pharmaceutical Compounding, was found to be commonly used by pharmacists. This project investigated the robustness of the compendium omeprazole high-performance liquid chromatographic assay in evaluating an oral liquid made from commercial delayed-release pellets, the potency of extemporaneously compounded solutions having a 1.125% v/v flavored versus unflavored samples stored at controlled cold temperatures at different time points, and examining the absorption spectrum of the flavoring agent. As part of the study, stability-indication testing was also conducted. The studies indicate that the chromatographic area under the plasma concentration-time curve of both study groups remained over 90% of the label claim during the follow-up period. The flavor did not significantly impact the pH of the oral liquid. This study further identified (1) an increase in resilient foam formation in the flavored liquid, potentially hindering dosing accuracy, (2) omeprazole is oxidized easily by 3% hydrogen peroxide, and (3) flavoring agent absorbs in an ultraviolet visible spectroscopy spectral range often used in assay detectors for quantification of drug molecules, and could interfere with assay protocols of the same.
[Mh] Termos MeSH primário: Aromatizantes/administração & dosagem
Omeprazol/química
Inibidores da Bomba de Prótons/química
[Mh] Termos MeSH secundário: Cromatografia Líquida de Alta Pressão
Preparações de Ação Retardada
Estabilidade de Medicamentos
Concentração de Íons de Hidrogênio
Omeprazol/administração & dosagem
Soluções
Espectrofotometria Ultravioleta
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Delayed-Action Preparations); 0 (Flavoring Agents); 0 (Proton Pump Inhibitors); 0 (Solutions); KG60484QX9 (Omeprazole)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171209
[St] Status:MEDLINE


  3 / 8365 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28468688
[Au] Autor:Rahman MS; Yoshida N; Tsuboi H; Keila T; Sovannarith T; Kiet HB; Dararth E; Zin T; Tanimoto T; Kimura K
[Ad] Endereço:Drug Management and Policy, Kanazawa University, Kanazawa, Japan. rahmansofique@gmail.com.
[Ti] Título:Erroneous formulation of delayed-release omeprazole capsules: alert for importing countries.
[So] Source:BMC Pharmacol Toxicol;18(1):31, 2017 May 03.
[Is] ISSN:2050-6511
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Poor drug quality is a matter of serious concern, especially in countries where drug regulation and law enforcement are constrained by limited resources. This study was carried out to investigate the cause of quality failure of omeprazole in Cambodia in 2010 and Myanmar in 2014. METHODS: We conducted pharmacopoeial quantity, content uniformity and dissolution tests of 156 samples of omeprazole capsules collected in Cambodia in 2010 and Myanmar in 2014. High failure rates were found, especially in dissolution testing, and detailed investigation of several unacceptable samples was carried out by means of in-vitro dissolution profiling, scanning electron microscopy (SEM) and X-ray computed tomography (X-ray CT) to identify the cause of failure. RESULTS: Dissolution profiling with and without the acid stage showed that acid caused premature omeprazole release, indicating that the enteric coating of the omeprazole granules was ineffective. SEM examination of two failed samples revealed cracked and broken granules mixed with apparently intact omeprazole granules in the capsule. X-ray CT examination indicated that some granules of failed samples completely lacked enteric coating, and others had incomplete and non-uniform enteric coating or malformation. CONCLUSIONS: Omeprazole capsules collected in Myanmar and Cambodia showed high failure rates in pharmacopoeial tests, especially dissolution tests. Some samples were found to have ineffective or absent enteric coating of the granules, resulting in premature dissolution and degradation in acidic conditions. This is a potentially serious public health issue that needs to be addressed by regulatory authorities in Cambodia and Myanmar, possibly through a collaborative initiative with manufacturers.
[Mh] Termos MeSH primário: Preparações de Ação Retardada/normas
Composição de Medicamentos/normas
Omeprazol/normas
[Mh] Termos MeSH secundário: Camboja
Cromatografia Líquida de Alta Pressão
Indústria Farmacêutica
Microscopia Eletrônica de Varredura
Mianmar
Vigilância de Produtos Comercializados
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Delayed-Action Preparations); KG60484QX9 (Omeprazole)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1186/s40360-017-0138-5


  4 / 8365 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27779491
[Au] Autor:Sen H; Oruç M; Isik VM; Sadiç M; Sayar H; Çitil R; Korkmaz M; Koçer U
[Ad] Endereço:From the *Adiyaman University Training and Research Hospital, Plastic, Reconstructive and Aesthetic Surgery Clinic, Adiyaman; †Ankara Training and Research Hospital Plastic, Reconstructive and Aesthetic Surgery Clinic, ‡Ankara Training and Research Hospital Nuclear Medicine Clinic, Ankara; §Faculty of Medicine, Pathology Department, Mersin University, Mersin; and ∥Kahramanmaras Necip Fazil City Hospital Pathology Clinic, Kahramanmaras, Turkey.
[Ti] Título:The Effect of Omeprazole Usage on the Viability of Random Pattern Skin Flaps in Rats.
[So] Source:Ann Plast Surg;78(6):e5-e9, 2017 Jun.
[Is] ISSN:1536-3708
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Necrosis of random pattern flaps caused by inadequate blood flow, especially in the distal part of the flap is one of the biggest challenges in reconstructive surgery. Various agents have been used to prevent flap ischemia. In this study, we used omeprazole, which is a potent inhibitor of gastric acidity to increase flap viability. METHODS: In this study, 35 Wistar-Albino type rats which were divided into 5 equal groups were used. Random-pattern dorsal skin flaps were raised in all groups at seventh day of the study. Group 1 was accepted as control group, and the rats in this group was only given distilled water intraperitoneally for 14 days. Group 2 and group 3 received 10 and 40 mg/kg omeprazole daily for 14 days, respectively. Group 4 and group 5 were given distilled water for the first 7 days and then after the operations they received 10 and 40 mg/kg omeprazole daily for 7 days, respectively. Survival rates of the flaps were examined seventh day after elevation of the flaps by digital imaging and scintigraphy. After assessment of the amount of necrosis, number of vascular structures were counted histopathologically. RESULTS: Percentage of flap necrosis was found to be less in all omeprazole received groups. On digital imaging, percentages of flap necrosis in the study groups were statistically significantly lower than that of the control group (P < 0.001), but there was no significant difference between the study groups (P > 0.05).In the histopathologic specimens, it was detected that the mean number of vessels in proximal (a) and distal (c) portions of the flap in the study groups showed a significant increase when compared with the control group (P < 0.01 for groups 2, 4 and 5, and P < 0.05 for group 3). CONCLUSIONS: In conclusion, possible clinical usage of medications increasing gastrin during flap surgeries can be thought as a positive contributor. In this sense, this study showed that parenteral administration of omeprazole in skin flap surgery increases flap viability possibly by increasing gastrin levels.
[Mh] Termos MeSH primário: Sobrevivência de Enxerto/efeitos dos fármacos
Omeprazol/farmacologia
Retalhos Cirúrgicos/irrigação sanguínea
[Mh] Termos MeSH secundário: Animais
Feminino
Interpretação de Imagem Assistida por Computador
Necrose/diagnóstico por imagem
Necrose/prevenção & controle
Omeprazol/administração & dosagem
Complicações Pós-Operatórias/diagnóstico por imagem
Complicações Pós-Operatórias/prevenção & controle
Ratos
Ratos Wistar
Transplante de Pele
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
KG60484QX9 (Omeprazole)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180129
[Lr] Data última revisão:
180129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1097/SAP.0000000000000922


  5 / 8365 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29245331
[Au] Autor:Li B; Ma H; Wang Z; Liu L
[Ad] Endereço:aDepartment of PharmacybDepartment of General Surgery, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
[Ti] Título:When omeprazole met with asymptomatic Clostridium difficile colonization in a postoperative colon cancer patient: A case report.
[So] Source:Medicine (Baltimore);96(49):e9089, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Clostridium difficile infection (CDI) is a symptomatic infection due to the spore-forming bacterium, C. difficile. Asymptomatic C. difficile colonization is the stage in absence of symptoms, with a prevalence of 1.4% to 21% on hospital admission. Proton-pump inhibitors (PPIs) was implicated as a novel potential contributor to CDI. PPIs injection could make asymptomatic C. difficile colonization progress to C. difficile associated diarrhea (CDAD). PATIENT CONCERNS: A postoperative colon cancer patient, who had been taking omeprazole for 4 years after operation, got asymptomatic C. difficile colonization. When he developed clinical symptoms of digestive tract, tumor recurrence was first suspected and intravenous omeprazole was prescribed, which ultimately led to progression to symptomatic CDI. In this report, we tell the confusing differential diagnosis of cancer-associated diseases and CDAD, and discuss the possibility of solving the PPIs overuse problem by making clinical pathway of PPIs use in Chinese hospitals. DIAGNOSES: CDAD, incomplete intestinal obstruction, postoperation of colon cancer. INTERVENTION: Electrolyte replacement and rehydration. Parenteral nutrition support. Omeprazole was prescribed but withdrawn later, and oral vancomycin was given at a dose of 0.25 g 4 times per day for 10 days. OUTCOMES: Diarrhea was resolved, so long as the acid reflux and vomiting. LESSONS: We have 2 lessons here: Be aware of PPIs induced CDI, especially the asymptomatic C. difficile colonization. Making clinical pathway specified on PPIs use by pharmacists could be a practical way to solve the problem of PPIs overuse.
[Mh] Termos MeSH primário: Infecções por Clostridium/induzido quimicamente
Neoplasias do Colo/cirurgia
Omeprazol/efeitos adversos
Inibidores da Bomba de Prótons/efeitos adversos
[Mh] Termos MeSH secundário: Idoso de 80 Anos ou mais
Diagnóstico Diferencial
Seres Humanos
Injeções Intravenosas
Masculino
Omeprazol/administração & dosagem
Inibidores da Bomba de Prótons/administração & dosagem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Proton Pump Inhibitors); KG60484QX9 (Omeprazole)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171217
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009089


  6 / 8365 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28953640
[Au] Autor:Li MJ; Li Q; Sun M; Liu LQ
[Ad] Endereço:aSchool of Pharmacy, Shanxi Medical University bDepartment of Pharmacy, The First Hospital of Shanxi Medical University, Taiyuan cDepartment of Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors & Hubei Cancer Clinical Study Center, Wuhan dDepartment of General Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, P.R. China.
[Ti] Título:Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
[So] Source:Medicine (Baltimore);96(39):e8120, 2017 Sep.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: This study compared the effectiveness and acceptability of all Food and Drug Administration (FDA)-recommended dose proton pump inhibitors (PPIs) in erosive esophagitis (EE): Dexlansoprazole 60 mg, Esomeprazole 40 mg, Esomeprazole 20 mg, Pantoprazole 40 mg, Lansoprazole 30 mg, Rabeprazole 20 mg, Omeprazole 20 mg. METHODS: A systematic literature search was performed using PubMed, Embase, and Cochrane Library. Totally, 25 randomized controlled trials (RCTs) met study selection criteria and were incorporated in this network meta-analysis (NMA) study. RESULTS: For the NMA, eligible RCTs of adults with EE verified by endoscopic examination were randomly assigned to the licensed PPIs at least 4 weeks of continuous therapy. The primary efficacy outcome was the endoscopic healing rates at 4 and 8 weeks. Heartburn relief rates were a secondary efficacy outcome. The rates of withdrawal were analyzed as a safety outcome. In comparison to the common comparator omeprazole 20 mg, esomeprazole 40 mg provided significantly healing rates at 4 weeks [odds ratio (OR), 1.46 (95% confidence interval, 95% CI, 1.24-1.71)] and 8 weeks [1.58 (1.29-1.92)], and improved the heartburn relief rates [1.29 (1.07-1.56)]. In comparison to lansoprazole 30 mg, esomeprazole 40 mg provided significantly healing rates at 4 weeks [1.30 (1.10-1.53)] and 8 weeks [1.37 (1.13-1.67)], and improved the heartburn relief rates [1.29 (1.03-1.62)]. In terms of acceptability, only dexlansoprazole 60 mg had significantly more all-cause discontinuation than omeprazole 20 mg [1.54 (1.03-2.29)], pantoprazole 40 mg [1.68 (1.08-2.63)], and lansoprazole 30 mg [1.38 (1.02-1.88)]. CONCLUSION: The standard-dose esomeprazole 40 mg had more superiority in mucosal erosion healing and heartburn relief. Esomeprazole 40 mg, pantoprazole 40 mg, esomeprazole 20 mg, and lansoprazole 30 mg showed more benefits in effectiveness and acceptability than other interventions.
[Mh] Termos MeSH primário: Esofagite Péptica/tratamento farmacológico
Inibidores da Bomba de Prótons/administração & dosagem
[Mh] Termos MeSH secundário: 2-Piridinilmetilsulfinilbenzimidazóis/administração & dosagem
Adulto
Pesquisa Comparativa da Efetividade
Dexlansoprazol/administração & dosagem
Esomeprazol/administração & dosagem
Esofagite Péptica/complicações
Feminino
Azia/tratamento farmacológico
Azia/etiologia
Seres Humanos
Lansoprazol/administração & dosagem
Masculino
Meia-Idade
Metanálise em Rede
Omeprazol/administração & dosagem
Rabeprazol/administração & dosagem
Resultado do Tratamento
Estados Unidos
United States Food and Drug Administration
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
0 (2-Pyridinylmethylsulfinylbenzimidazoles); 0 (Proton Pump Inhibitors); 0K5C5T2QPG (Lansoprazole); 32828355LL (Rabeprazole); D8TST4O562 (pantoprazole); KG60484QX9 (Omeprazole); N3PA6559FT (Esomeprazole); UYE4T5I70X (Dexlansoprazole)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008120


  7 / 8365 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28842999
[Au] Autor:Carroll TL; Werner A; Nahikian K; Dezube A; Roth DF
[Ad] Endereço:Department of Surgery, Division of Otolaryngology, Brigham and Women's Hospital, Boston, Massachusetts, U.S.A.
[Ti] Título:Rethinking the laryngopharyngeal reflux treatment algorithm: Evaluating an alternate empiric dosing regimen and considering up-front, pH-impedance, and manometry testing to minimize cost in treating suspect laryngopharyngeal reflux disease.
[So] Source:Laryngoscope;127 Suppl 6:S1-S13, 2017 Oct.
[Is] ISSN:1531-4995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES/HYPOTHESIS: Empiric proton pump inhibitor (PPI) trials for laryngopharyngeal reflux (LPR) are common. A majority of the patients respond to acid suppression. This work intends to evaluate once-daily, 40 mg omeprazole and once-nightly, 300 mg ranitidine (QD/QHS) dosing as an alternative regimen, and use this study's cohort to evaluate empiric regimens prescribed for LPR as compared to up-front testing with pH impedance multichannel intraluminal impedance (MII) with dual pH probes and high-resolution manometry (HRM) for potential cost minimization. STUDY DESIGN: Retrospective cohort review and cost minimization study. METHODS: A chart review identified patients diagnosed with LPR. All subjects were treated sequentially and outcomes recorded. Initial QD/QHS dosing increased after 3 months to BID if no improvement and ultimately prescribed MII and HRM if they failed BID dosing. Decision tree diagrams were constructed to determine costs of two empiric regimens and up-front MII and HRM. RESULTS: Ninety-seven subjects met the criteria. Responders and nonresponders to empiric therapy were identified. Seventy-two subjects (74%) responded. Forty-eight (67% of responders and 49% of all) improved with QD/QHS dosing. Forty-nine (51%) subjects escalated to BID dosing. Twenty-four subjects (33% of responders and 25% of all) improved on BID therapy. Twenty-five subjects (26%) did not respond to acid suppression. Average weighted cost was $1,897.00 per patient for up-front testing, $3,033.00 for initial BID, and $3,366.00 for initial QD/QHS. CONCLUSIONS: An alternate QD/QHS regimen improved the majority who presented with presumed LPR. Cost estimates demonstrate that the QD/QHS regimen was more expensive than the initial BID high-dose PPI for 6 months. Overall per-patient cost appears less with up-front MII and HRM. LEVEL OF EVIDENCE: 4. Laryngoscope, 127:S1-S13, 2017.
[Mh] Termos MeSH primário: Algoritmos
Antiulcerosos/administração & dosagem
Análise Custo-Benefício
Monitoramento do pH Esofágico/economia
Refluxo Laringofaríngeo/tratamento farmacológico
Manometria/economia
Inibidores da Bomba de Prótons/administração & dosagem
[Mh] Termos MeSH secundário: Antiulcerosos/economia
Esquema de Medicação
Quimioterapia Combinada/economia
Quimioterapia Combinada/métodos
Impedância Elétrica
Monitoramento do pH Esofágico/métodos
Feminino
Seres Humanos
Refluxo Laringofaríngeo/economia
Refluxo Laringofaríngeo/fisiopatologia
Masculino
Manometria/métodos
Meia-Idade
Omeprazol/administração & dosagem
Omeprazol/economia
Inibidores da Bomba de Prótons/economia
Ranitidina/administração & dosagem
Ranitidina/economia
Estudos Retrospectivos
Resultado do Tratamento
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Ulcer Agents); 0 (Proton Pump Inhibitors); 884KT10YB7 (Ranitidine); KG60484QX9 (Omeprazole)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170929
[Lr] Data última revisão:
170929
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170827
[St] Status:MEDLINE
[do] DOI:10.1002/lary.26806


  8 / 8365 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28803655
[Au] Autor:Kagolanu D; Sayedy N; Haseeb S; Shah S; Lam P; Munnangi S; Viswanathan P; Stephenson K
[Ad] Endereço:Department of Internal Medicine, Nassau University Medical Center, East Meadow, USA. Electronic address: deepthi.lank@gmail.com.
[Ti] Título:Usefulness of PA32540 in Protecting the Gastric Layer While Providing Secondary Prevention for Coronary Artery Disease.
[So] Source:Am J Cardiol;120(7):1118-1121, 2017 Oct 01.
[Is] ISSN:1879-1913
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Aspirin has been the mainstay for secondary prevention of coronary artery disease to decrease early recurrence and severity of recurrent cardiovascular events. However, an increase in gastrointestinal bleeding due to aspirin is preventing many patients from adhering to this daily regimen. PA32540, a combination pill with aspirin and omeprazole, is a newly emerging intervention that has the potential to reinforce patient compliance with the aspirin regimen due to fewer gastrointestinal adverse effects. This systematic review assessed three recent phase 3 clinical trials investigating the safety and efficacy of PA32540. Clinical trials were chosen based on inclusion criteria such as phase 3, randomized, open-label or blinded studies, utilization of enteric-coated aspirin 325 mg dose, and measured GI adverse effects and major adverse cardiac events (MACE) as primary outcomes. Study A, a 6-month phase-3 study by Whellan et al., used two identically designed, randomized, double-blind trials to compare the GI adverse events and MACE after the use of PA32540 to 325mg of enteric coated Aspirin (EC-ASA) in subjects at risk for aspirin-associated gastric ulcers. Results showed fewer upper GI symptoms, decreased size of ulcers, and improved heartburn symptoms in subjects receiving PA32540 compared to EC-ASA. Study B, a 12-month phase-3 study by Hatoum et al., assessed secondary cardiovascular event prevention in a study population that was treated with PA32540 in comparison to a community setting (CS) group that was started on a standard antiplatelet treatment. Results indicated a 28% reduction of CV events in subjects treated with PA32540 compared to the CS group. Study C, a phase-3 open-label study by Goldstein et al., evaluating secondary prevention of cardiovascular/cerebrovascular events with the use of PA32450 for 12 months found that none of the 12-month completers were reported to have new-onset gastric ulcers. In conclusion, PA32540 could be an effective therapy for secondary prevention of coronary artery disease as studies are showing similar efficacy in preventing MACE with reduced GI side effects.
[Mh] Termos MeSH primário: Aspirina/efeitos adversos
Doença da Artéria Coronariana/prevenção & controle
Mucosa Gástrica/efeitos dos fármacos
Hemorragia Gastrointestinal/prevenção & controle
Omeprazol/administração & dosagem
Prevenção Secundária/métodos
[Mh] Termos MeSH secundário: Administração Oral
Aspirina/administração & dosagem
Método Duplo-Cego
Combinação de Medicamentos
Mucosa Gástrica/patologia
Hemorragia Gastrointestinal/induzido quimicamente
Seres Humanos
Inibidores da Agregação de Plaquetas/administração & dosagem
Inibidores da Bomba de Prótons/administração & dosagem
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Drug Combinations); 0 (Platelet Aggregation Inhibitors); 0 (Proton Pump Inhibitors); KG60484QX9 (Omeprazole); R16CO5Y76E (Aspirin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170914
[Lr] Data última revisão:
170914
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170815
[St] Status:MEDLINE


  9 / 8365 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28763499
[Au] Autor:Andrade PHS; Lobo IMF; da Silva WB
[Ad] Endereço:Universidade Federal de Sergipe, São Cristóvão, Sergipe, Brazil.
[Ti] Título:Risk factors for adverse drug reactions in pediatric inpatients: A cohort study.
[So] Source:PLoS One;12(8):e0182327, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The present study aims to identify the risk factors for adverse drug reactions (ADR) in pediatric inpatients. METHODS: A prospective cohort study in one general pediatric ward in a hospital in Northeast Brazil was conducted in two stages: the first stage was conducted between August 17th and November 6th, 2015, and the second one between March 1st and August 25th, 2016. We included children aged 0-14 years 11 months hospitalized with a minimum stay of 48 hours. Observed outcomes were the ADR occurrence and the time until the first ADR observed. In the univariate analysis, the time to the first ADR was compared among groups using a log-rank test. For the multivariate analysis, the Cox regression model was used. RESULTS: A total of 173 children (208 admissions) and 66 ADR classified as "definite" and "probable" were identified. The incidence rate was 3/100 patient days. The gastro-intestinal system disorders were the main ADR observed (28.8%). In addition, 22.7% of the ADR were related to antibacterials for systemic use and 15.2% to general anesthesia. Prior history of ADR of the child [hazard ratio (HR) 2.44; 95% confidence interval (CI) 1.19-5.00], the use of meglumine antimonate (HR 4.98; 95% CI 1.21-20.54), antibacterial for systemic use (HR 2.75; 95% CI 1.08-6.98) and antiepileptic drugs (HR 3.84; 95% CI 1.40-10.56) were identified risk factors for ADR. CONCLUSIONS: We identified as risk factors the prior history of ADR of the child and the use of meglumine antimonate, antibacterial for systemic use and antiepileptic drugs.
[Mh] Termos MeSH primário: Antibacterianos/efeitos adversos
Anticonvulsivantes/efeitos adversos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia
Meglumina/efeitos adversos
[Mh] Termos MeSH secundário: Adolescente
Sistemas de Notificação de Reações Adversas a Medicamentos
Anestesia Geral
Brasil
Criança
Pré-Escolar
Clonazepam/efeitos adversos
Estudos de Coortes
Fibrose Cística/tratamento farmacológico
Dipirona/efeitos adversos
Feminino
Gastroenteropatias/complicações
Gastroenteropatias/tratamento farmacológico
Hospitalização
Hospitais Pediátricos
Seres Humanos
Lactente
Recém-Nascido
Pacientes Internados
Masculino
Omeprazol/efeitos adversos
Pediatria
Projetos Piloto
Modelos de Riscos Proporcionais
Análise de Regressão
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Anticonvulsants); 5PE9FDE8GB (Clonazepam); 6429L0L52Y (Dipyrone); 6HG8UB2MUY (Meglumine); KG60484QX9 (Omeprazole)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170802
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0182327


  10 / 8365 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28522175
[Au] Autor:Goswami SK; Rand AA; Wan D; Yang J; Inceoglu B; Thomas M; Morisseau C; Yang GY; Hammock BD
[Ad] Endereço:Department of Entomology and Nematology, and Comprehensive Cancer Center, University of California, Davis, CA 95616, USA.
[Ti] Título:Pharmacological inhibition of soluble epoxide hydrolase or genetic deletion reduces diclofenac-induced gastric ulcers.
[So] Source:Life Sci;180:114-122, 2017 Jul 01.
[Is] ISSN:1879-0631
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:AIMS: This research was conducted to evaluate the hypothesis that gastric ulcers caused by the NSAID diclofenac sodium (DCF) can be prevented by the soluble epoxide hydrolase inhibitor TPPU. MAIN METHODS: Mice were administered a single dose of 10, 30 or 100mg/kg of DCF. Once an ulcerative dose of DCF was chosen, mice were pretreated with TPPU for 7days at 0.1mg/kg to evaluate anti-ulcer effects of the sEH inhibitor on anatomy, histopathology, pH, inflammatory markers and epithelial apoptosis of stomachs. KEY FINDINGS: Diclofenac caused ulceration of the stomach at a dose of 100mg/kg and a time post dose of 6h. Ulcers generated under these conditions were associated with a significant increase in the levels of TNF-α and IL-6 in serum and increased apoptosis compared to control mice. Pretreatment with TPPU resulted in a decrease of ulceration in mice treated with DCF with a significant decrease in the level of apoptosis, TNF-α and IL-6 in the serum in comparison to diclofenac-treated mice. TPPU did not affect the pH of the stomach, whereas omeprazole elevated the pH of the stomach as expected. A similar anti-ulcer effect was observed in sEH gene knockout mice treated with DCF. SIGNIFICANCE: The sEH inhibitor TPPU decreases the NSAID-induced stomach ulcers.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/toxicidade
Diclofenaco/toxicidade
Epóxido Hidrolases/antagonistas & inibidores
Compostos de Fenilureia/farmacologia
Piperidinas/farmacologia
Úlcera Gástrica/prevenção & controle
[Mh] Termos MeSH secundário: Animais
Anti-Inflamatórios não Esteroides/administração & dosagem
Antiulcerosos/farmacologia
Apoptose/efeitos dos fármacos
Diclofenaco/administração & dosagem
Relação Dose-Resposta a Droga
Inibidores Enzimáticos/farmacologia
Epóxido Hidrolases/genética
Deleção de Genes
Concentração de Íons de Hidrogênio
Interleucina-6/sangue
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Camundongos Knockout
Omeprazol/farmacologia
Úlcera Gástrica/patologia
Fatores de Tempo
Fator de Necrose Tumoral alfa/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (1-trifluoromethoxyphenyl-3-(1-propionylpiperidine-4-yl)urea); 0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Anti-Ulcer Agents); 0 (Enzyme Inhibitors); 0 (Interleukin-6); 0 (Phenylurea Compounds); 0 (Piperidines); 0 (Tumor Necrosis Factor-alpha); 144O8QL0L1 (Diclofenac); EC 3.3.2.- (Epoxide Hydrolases); KG60484QX9 (Omeprazole)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170520
[St] Status:MEDLINE



página 1 de 837 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde